Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

NCT04773067 is registered in ClinicalTrials.gov with United Biomedical Inc., Asia as lead sponsor.

NCT NCT04773067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers
Lead sponsor
United Biomedical Inc., Asia
Phase
Phase 2
Overall status
Terminated
Start date
January 30, 2021
Completion date
March 8, 2022
Enrollment
3,877 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19